Focused On-demand Library for Biliverdin reductase A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Biliverdin-IX alpha-reductase

Alternative UPACC:

P53004; A8K747; O95019; Q86UX0; Q96QL4; Q9BRW8


Biliverdin reductase A, also known as Biliverdin-IX alpha-reductase, plays a pivotal role in the heme degradation pathway. It catalyzes the conversion of biliverdin IX alpha to bilirubin, utilizing NADH or NADPH as cofactors. This enzyme's activity is crucial for maintaining the balance between biliverdin and bilirubin levels in the body, with preferences for NADH in acidic conditions and NADPH in alkaline.

Therapeutic significance:

Hyperbiliverdinemia, characterized by green discoloration of the skin and bodily fluids, is linked to mutations affecting Biliverdin reductase A. Understanding the role of Biliverdin reductase A could open doors to potential therapeutic strategies for treating this condition and related disorders of bilirubin metabolism.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.